IVA

Inventiva SA (IVA) is a clinical-stage biopharmaceutical company based in Daix, France, focused on developing innovative oral small molecule therapies for significant unmet medical needs, particularly in non-alcoholic steatohepatitis (NASH) and mucopolysaccharidosis (MPS). The company boasts a promising pipeline of proprietary drug candidates that target complex metabolic and rare diseases. As Inventiva moves closer to pivotal clinical trials, it is well-positioned to potentially transform patient outcomes while creating substantial value within the biopharmaceutical industry.